Related Experiment Video

Updated: Mar 12, 2026

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model
09:44

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Published on: March 5, 2022

3.5K

Pathologic significance of SET/I2PP2A-mediated PP2A and non-PP2A pathways in polycystic ovary syndrome (PCOS)

Shi-Wen Jiang1, Siliang Xu2, Haibin Chen3

  • 1Department of Obstetrics and Gynecology, The Second Affiliated Hospital, Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China; Department of Biomedical Science, Mercer University School of Medicine, Savannah, GA, USA.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|November 13, 2016
PubMed

Insights

The SET protein, an inhibitor of PP2A, is linked to polycystic ovary syndrome (PCOS) by increasing androgen production. Targeting SET may offer a new therapy for PCOS hyperandrogenism.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Oncology

Background:

  • SET (SE translocation) is a multifunctional oncoprotein inhibiting protein phosphatase 2A (PP2A).
  • Overexpressed SET is implicated in Alzheimer's disease, breast, and ovarian cancers.
  • SET's interaction with PP2A may drive androgen biosynthesis and hyperandrogenism in PCOS.

Purpose of the Study:

  • To review SET expression in ovaries of PCOS and normal women.
  • To analyze SET's role and regulatory mechanism in PCOS androgen biosynthesis.
  • To discuss SET as a therapeutic target for PCOS hyperandrogenism.

Main Methods:

  • Literature review of studies on SET expression and function.
  • Analysis of data concerning SET in PCOS ovarian tissue.
  • Examination of SET's interaction with PP2A and androgen synthesis pathways.

Main Results:

  • SET is expressed in human ovaries and its dysregulation is observed in PCOS.
  • SET interaction with PP2A upregulates androgen biosynthesis, contributing to PCOS.
  • SET pathway activation is significant in the pathogenesis of PCOS.

Conclusions:

  • SET plays a crucial role in PCOS-related hyperandrogenism.
  • The SET-PP2A pathway represents a potential therapeutic target for PCOS.
  • Anti-SET reagents may offer a novel treatment strategy for PCOS hyperandrogenism.
Keywords:
AndrogenAnti-SETHyperandrogenismPCOSPP2ASET

More Related Videos

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome04:49

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome

Published on: July 5, 2024

1.9K
A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome08:20

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome

Published on: October 2, 2018

12.0K

Related Concept Videos

Oogenesis02:07

Oogenesis

In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
70.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Meiosis II02:02

Meiosis II

Meiosis II entails cell division and segregation of the sister chromatids, resulting in the production of four unique haploid gametes. The steps for meiosis II are similar to mitosis, except that meiosis II occurs in haploid cells, whereas mitosis occurs in diploid cells.
The timing and cell division patterns of meiosis differ between males and females. In male meiosis, the centrosomes are part of the formation of the meiotic spindle. However, in oocytes, including that of humans, Drosophila,...
51.3K
Meiosis II01:57

Meiosis II

Meiosis II is the second and final stage of meiosis. It relies on the haploid cells produced during meiosis I, each of which contain only 23 chromosomes—one from each homologous initial pair. Importantly, each chromosome in these cells is composed of two joined copies, and when these cells enter meiosis II, the goal is to separate such sister chromatids using the same microtubule-based network employed in other division processes. The result of meiosis II is two haploid cells, each...
209.9K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K